Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Wisconsin, Madison
rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Untreated mantle cell lymphoma
You may not be if
Pregnant or breast feeding
Clareo Health | Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
